Prospective evaluation of Epstein-Barr Virus reactivation after stem cell transplantation: Association with monoclonal gammopathy

Journal of Clinical Immunology

Volumn 30, Issue 6, 2010, Pages 894-902

  Chiusolo, Patrizia ^a   Metafuni, Elisabetta ^a   Cattani, Paola ^c   Piccirillo, Nicola ^a   Santangelo, Rosaria ^c   Manzara, Stefania ^c   Bellesi, Silvia ^a   De Michele, Teresa ^b   Leone, Giuseppe ^a   Sica, Simona ^a  

^a Institute of Haematology   (Italy)

^b Institute of Biochemistry and Clinical Biochemistry   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

EBV; Monoclonal gammopathy; PTLD; Stem cell transplantation

Indexed keywords

RITUXIMAB;

AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ELECTROPHORESIS; RISK FACTOR; SCHOOL CHILD; STEM CELL TRANSPLANTATION; VIREMIA; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; VIRAL LOAD; VIRUS ACTIVATION;

EID: 78651336724     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9454-x     Document Type: Article

References (24)

1. Capello D, Rasi S, Oreste P, Veronese S, Cerri M, Ravelli E, et al. Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. J Pathol. 2009;218:478-86.
2. Henslop H. How I treat EBV lymphoproliferation. Blood. 2009;114:4002-8.
3. Van Esser JWJ, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98:972-8.
4. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, et al. Management of HSV. VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on infectious in Leukemia. Bone Marrow Transplant. 2009;43:757-70.
5. Van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus limphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364-70.
6. Reddiconto G, Chiusolo P, Fiorini A, Farina G, Laurenti L, Martini M, et al. Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. Leukemia. 2007;21:2552-4.
7. Danger JJM, Langerak AW, Brüggemann M, Evans PAS, Hummel M, Laverder FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombination in suspect lymphoproliferation: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17:2257-317.
8. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate the peripheral blood of immunosuppressed patients. J Exp Med. 1999;190:567-76.
9. Awaya N, Adachi A, Mori T, Kamata H, Nakahara J, Yokojama K, et al. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma. Leuk Res. 2006;30:1059-62.
10. Peniket AJ, Perry AR, Williams CD, MacMillan A, Watts MJ, Isaacson PG, et al. A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1998;22(3):307-9.
11. Rosselet A, Vu DH, Meylan P, Baur Chaubert AS, Schapira M, Pascual M, et al. Association of serum EBV DNA and gammopathy with post-transplant lymphoproliferative disease. Clin Transplant. 2009;23:74-82.
12. Chakrabarti S, Milligan DW, Pillay D, Mackinnon S, Holder K, Kaur N, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and non-myeloablative allogeneic stem cell transplantation. Blood. 2003;102:839-42.
13. Cohen JM, Cooper N, Chakrabarti S, Thomson K, Samarasinghe S, Cubitt D, et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma. 2007;48:256-69.
14. Juvonen E, Aalto SM, Tarkkanen J, Mattila PS, Knuutila S, Ruutu T, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant. 2003;32:97-102.
15. Bruinstein CG, Weisdorf DJ, De For T, Barker JN, Tolar J, van Burik JA, et al. Marked increased risk of Epstein-Barr virusrelated complications with the addition of antithymocyte globuline to a non-myeloablative conditioning prior of unrelated umbilical cord blood transplantation. Blood. 2006;108:2874-80.
16. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive interventions for EBV lymphoproliferative disease. Blood. 2004;103:3979-81.
17. Badley AD, Portela DF, Patel R, Kyle RA, Habermann TM, Strickler JG, et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transplant Surg. 1996;2:375-82.
18. Lemoine A, Pham P, Azoulay D, Saliba F, Saffroy R, Broet P, et al. Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplant. Blood. 2001;98:1332-8.
19. Babel N, Schwarzmann F, Pruss A, Volk HD, Reinke P. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplant Proc. 2004;36:2679-82.
20. Tsai DE, Aqui NA, Tomaszewski JE, Olthoff KM, Ahya VN, Kotloff RM, et al. Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder. Clin Transplant. 2005;19:644-52.
21. Mitus AJ, Stein R, Rappeport JM, Antin JH, Alper CA, Smith BR. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood. 1989;74:2764-8.
22. Nagashima T, Muroi K, Kawano-Yamamoto C, Komatsu N, Ozawa K. Paraproteinemia after haematopoietic stem cell transplantation. Leuk Lymphoma. 2004;45(1):135-7.
23. Lim ZY, Ingram W, Brand R, Akthari M, Milojkovic D, Ho AY, et al. Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft versus host disease and improved overall survival. Bone Marrow Transplant. 2007;40:747-52.
24. Sorà F, Laurenti L, Chiusolo P, De Matteis S, Leone G, Sica S. Clonal gammopathy and allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;41:317.